Comparing a new hemostasis test with standard methods for patients on heparin therapy
Official title: Comparison of the 'CTR' Ratio With Standard Haemostasis Parameters in the Follow-up of Patients Undergoing Heparin Therapy
Run by Direction Centrale du Service de Santé des Armées · NCT05993533 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new blood test to see if it can better help doctors monitor patients on heparin therapy for blood clots compared to standard methods.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Direction Centrale du Service de Santé des Armées Academic / other |
| Locations | 1 site (Saint-Mandé) |
| Trial ID | NCT05993533 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 who are on curative heparin therapy and have anti-Xa activity monitoring prescribed.
✕Probably not a fit
Patients who are unable to consent, not on anticoagulant treatment, or those who are pregnant or breastfeeding may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the effectiveness of the Quantra hemostasis analyzer in monitoring patients undergoing heparin therapy for venous thromboembolic disease. The analyzer uses ultrasound technology to assess the viscoelastic properties of blood during coagulation, providing real-time insights at the patient's bedside. By measuring multiple hemostatic parameters simultaneously, the study aims to improve the management of coagulation disorders and optimize treatment strategies for patients receiving heparin. The study focuses on patients who are prescribed anti-Xa activity monitoring as part of their treatment plan.
Why it matters
Potential benefit: If successful, this study could enhance the monitoring of coagulation in patients on heparin, leading to better management of their treatment and potentially improved outcomes.
How similar studies have gone: While this approach is relatively novel, similar studies using advanced hemostasis testing have shown promise in improving patient outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 and affiliated to the french social security system * Patients on curative heparin (low molecular weight heparin or non-fractionated heparin) for whom anti-Xa activity is prescribed or planned by the clinician * Samples taken between working hours * No opposition to study participation Exclusion Criteria: * Patients unable to consent * Anti-Xa activity not prescribed * Patients on another anticoagulant treatment or not anticoagulated about it * Samples taken during non-working hours * Pregnant or breast-feeding women * Insufficient language level for understanding the information note
Where it's running
-
HIA Bégin
Saint-Mandé, France Recruiting
Study contacts
- Study coordinator: Aurore BOUSQUET
- Email: aurore.bousquet@intradef.gouv.fr
- Phone: 1 43 98 52 18
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Reduced‑dose apixaban or rivaroxaban versus daily low‑molecular‑weight heparin for people with blood cancers
This trial will test whether reduced‑dose apixaban or rivaroxaban pills can prevent blood clots as well and as safely as daily low‑molecular‑weight heparin injections in people with hematologic malignancies.
-
Monitoring adults after venous thromboembolism
This project tests whether using bleeding-and-recurrence risk scores together with multidisciplinary thrombosis meetings helps guide anticoagulant treatment for adults hospitalized with venous thromboembolism.
-
Examining blood clotting in pregnant women and the effects of low molecular weight heparin
This study looks at how blood clotting changes during and after pregnancy to see if a blood thinner called low molecular weight heparin works better for pregnant women at risk of blood clots.
-
Comparing antithrombotic therapies for patients with acute venous thromboembolism and a history of cardiovascular disease
This study is testing if combining blood thinners with another type of medication can help people with blood clots and a history of heart disease stay safe and healthy.
-
Prolonged anticoagulation for preventing blood clots in autoimmune hemolytic anemia
This study is testing if longer use of blood thinners can help prevent blood clots in people with autoimmune hemolytic anemia.
-
CHIPs-VTE program to prevent hospital-acquired blood clots in hospitalized patients
This project tests whether a hospital-wide package of risk checks, computer alerts, staff education, and audits can increase appropriate clot-prevention for hospitalized patients in China.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.